Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901166 | 0.80 | KMT2A (0.50) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL3767629 | 0.78 | HPRT1 (0.47) | KMT2AMEN1ALDH1A1HSD17B10TSHR | |
| SCHEMBL15082603 | 0.77 | KMT2A (0.45) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL2121863 | 0.77 | KMT2A (0.51) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL29852 | 0.77 | TDP1 (0.47) | KMT2AMEN1ALDH1A1HPGDTDP1 | |
| SCHEMBL9815022 | 0.77 | ALDH1A1 (0.48) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL2939780 | 0.77 | KMT2A (0.47) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL2939781 | 0.77 | KMT2A (0.47) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL8927201 | 0.76 | KMT2A (0.47) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL67895 | 0.76 | KMT2A (0.47) | KMT2AMEN1ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130052690-A1 | PCR PRIMER AND METHOD FOR REDUCING NON-SPECIFIC NUCLEIC ACID AMPLIFICATION USING A PHOTOLABILE PROTECTING GROUP | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-02-28 | — | — | US | claimed |
| US-8246754-B2 | Process for removing ink from printed substrate | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2012-08-21 | — | — | US | claimed |
| US-7087732-B2 | Nucleotides and analogs having photoremovable protecting groups | AFFYMETRIX, INC. (US) | 2006-08-08 | — | — | US | claimed |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240092799-A1 | MNK INHIBITORS | HEPAGENE THERAPEUTICS HK LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| US-11708374-B2 | Preparation of condensed triazepine derivatives and their use as BET inhibitors | Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) | 2023-07-25 | — | — | US | disclosed |
| CN-116490505-A | MNK inhibitors | 和博医药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4200296-A1 | MNK INHIBITORS | Hepagene Therapeutics (HK) Limited (HK) | 2023-06-28 | — | — | EP | disclosed |
| US-20230092024-A1 | Increasing Efficiency Of Photochemical Reactions On Substrates | CENTRILLION TECHNOLOGIES, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-1994006808-A1 | METHODS FOR THE SYNTHESIS OF PHOSPHONATE ESTERS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1994-03-31 | — | — | WO | disclosed |
| EP-0562025-A4 | — | — | 1994-03-30 | — | — | EP | disclosed |
| US-5288514-A | Linking a protected 2-aminobenzophenone to a substrate; deprotecting and reacting with an amino acid; cyclization; removal from substrate; screening | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-02-22 | — | — | US | disclosed |
| US-5252743-A | Using cage binding compound | AFFYMAX TECHNOLOGIES N.V. (NL) | 1993-10-12 | — | — | US | disclosed |
| EP-0562025-A1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-09-29 | — | — | EP | disclosed |
| EP-0502060-A4 | SPATIALLY-ADDRESSABLE IMMOBILIZATION OF ANTI-LIGANDS ON SURFACES | — | 1993-05-05 | — | — | EP | disclosed |
| EP-0502060-A1 | SPATIALLY-ADDRESSABLE IMMOBILIZATION OF ANTI-LIGANDS ON SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1992-09-09 | — | — | EP | disclosed |
| WO-1992010092-A1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1992-06-25 | — | — | WO | disclosed |
| WO-1991007087-A1 | SPATIALLY-ADDRESSABLE IMMOBILIZATION OF ANTI-LIGANDS ON SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052690-A1 | PCR PRIMER AND METHOD FOR REDUCING NON-SPECIFIC NUCLEIC ACID AMPLIFICATION USING A PHOTOLABILE PROTECTING GROUP | POLL, POLRMT, POLN | KMT2A 1919/4885MEN1 2119/4885ALDH1A1 1877/4885 |
| US-20240092799-A1 | MNK INHIBITORS | MKNK1, MATK, NEK1 | KMT2A 443/4885MEN1 713/4885ALDH1A1 4526/4885 |
| US-20230092024-A1 | Increasing Efficiency Of Photochemical Reactions On Substrates | TYR, PCNA, DNMT1 | KMT2A 1427/4885MEN1 3754/4885ALDH1A1 1455/4885 |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | KMT2A 767/4885MEN1 194/4885ALDH1A1 4638/4885 |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | BTK, ABL1, LYN | KMT2A 1188/4885MEN1 3314/4885ALDH1A1 4045/4885 |
| US-11708374-B2 | Preparation of condensed triazepine derivatives and their use as BET inhibitors | BET1, EP300, BICRA | KMT2A 292/4885MEN1 920/4885ALDH1A1 4080/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | KMT2A 4440/4885MEN1 3607/4885ALDH1A1 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.